Cutaneous reactions to imatinib therapy are increasingly being recognized, with up to 21% of patients experiencing mild to moderate reactions at doses of 600 mg and higher.[1][1] A recent case report of Stevens-Johnson syndrome complicating the use of imatinib[2][2] expressed caution in the
No takes yet. Share an insight, caveat, or question.
Rule et al. (2002) studied this question.